Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Trastuzumab som adjuvant behandling avbröstcancerpatienter med HER2-positivitet: Hur effektivt är det?
Linnaeus University, Faculty of Science and Engineering, School of Natural Sciences.
2011 (Swedish)Independent thesis Basic level (degree of Bachelor), 10 credits / 15 HE creditsStudent thesis
Abstract [en]

Breast cancer is the most common tumor disease among women in Sweden. About 7000persons, having a median age of 65, are diagnosed each year with this disease. Withmammography screening, breast cancer can be detected in an early stage which improves theoverall survival (OS). 20-30 % of the breast cancer tumors are overexpressing humanepidermal growth factor receptor 2 (HER2), which is a protein that stimulates cell proliferation.Trastuzumab (Herceptin®) is a humanised monoclonal antibody that targets the HER2-proteinand prevent the signals for cell proliferation.Trastuzumab has earlier been used for treatment of metastatic breast cancer. In the year of 2007trastuzumab was approved for adjuvant treatment of patients who has been medicated withsurgery and/or radiation.The aim of this study was to investigate the effects of adjuvant treatment with trastuzumab inHER2-positive breast cancer patients. The method was a literature study based on scientificarticles identified from the database PubMed.The articles that were choosen were two meta-analysis and three cohort studies. The benefitsand effects of trastuzumab administration on patients with HER2-positive breast cancer weredescribed in these articles. Primary endpoint was disease-free survival (DFS). All articlesshowed that the DFS increased in breast cancer patients treated with adjuvant trastuzumab but alonger follow-up of four years, showed a reduction of both DFS and OS.The conclusion of this study was that trastuzumab as adjuvant treatment is favorable and shouldbe considered as treatment of breast cancer with HER2 overexpression that has been analyzedby immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH).

Place, publisher, year, edition, pages
2011. , 33 p.
Keyword [sv]
trastuzumab, bröstcancer, HER2
National Category
Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:lnu:diva-11721OAI: oai:DiVA.org:lnu-11721DiVA: diva2:417359
Subject / course
Pharmacy
Educational program
Bachelor of Science Programme in Pharmacy, 180 credits
Uppsok
Medicine
Supervisors
Examiners
Available from: 2011-07-01 Created: 2011-05-16 Last updated: 2011-07-01Bibliographically approved

Open Access in DiVA

fulltext(411 kB)1216 downloads
File information
File name FULLTEXT01.pdfFile size 411 kBChecksum SHA-512
3355dd941da661d2b47ce0c45325454abd272f02dfc7f5d7c5d6859ad6c4863e622ec4d639b6b3190a32462cb0a2eb62b5553fb39421a8aa2db8f8c07504b5b0
Type fulltextMimetype application/pdf

By organisation
School of Natural Sciences
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 1216 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

urn-nbn

Altmetric score

urn-nbn
Total: 326 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf